Precigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Conference Call March 19, 2024 4:30 PM ET
Company Participants
Steve Harasym - Vice President, Investor Relations
Helen Sabzevari - President & Chief Executive Officer
Harry Thomasian - Chief Financial Officer
Jim Shaffer - Head of our Commercial
Conference Call Participants
Jason Butler - Citizens JMP
Jennifer Kim - Cantor Fitzgerald
Swayampakula Ramakanth - H.C. Wainwright
Brian Cheng - JPMorgan
Operator
Good afternoon and welcome to the Precigen Full-Year 2023 Financial Results and Update Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] Please note this event is being recorded.
I would like to turn the conference over to Steve Harasym, Vice President of Investor Relations. Please go ahead.
Steve Harasym
Thank you and I apologize for any technical difficulty here. Again, welcome to our 2023 full year financial call. With me are CEO, Helen Sabzevari; CFO, Harry Thomasian and Jim Shaffer. Please refer to our most recent filings for our forward looking statements.
With that, I'll turn the call over to Helen. Thank you.
Helen Sabzevari
Thank you, Steve, and thank you to everyone for joining us. And, again, apologies for this little bit of technical problems. But I think we are going through a very, very transformative year. 2024 is poised to be a transformational year for Precigen. We are on track to present a pivotal Phase 2 data for our lead asset PRGN-2012 in Q2 and intend on submitting our BLA in the second half of 2024. This is due in part to the positive guidance and pathway provided by the FDA and to the tireless work done by our team over the last several years, starting from discovery in 2020 all the way to the potential filings in 2024.
For today's call, I will focus on our AdenoVerse platform and we are working rapidly and prudently to advance our, obviously, our UltraCAR assets and we are looking forward to the [radar] readout later on this year for UltraCAR platform, as we outline as we outlined in today's press release.
So for today, let me just jump into our AdenoVerse platform, why we are excited about this platform and our lead assets that it pays off. For those of you who might not be familiar with this platform, this is a very differentiated platform from the rest of the viral platform. Why do I say that? It's very simple. First of all, this platform is built based on the library of the gorilla adenovector. These adenovectors are not like other adenovectors. First of all, they have a high capacity that you can put number of genes in them. But more importantly, they have the ability because there is no preimmunity in humans or very little. You can keep dosing with this vector.